Hypothesis

Individuals with higher baseline abundance of short‑chain fatty acid (SCFA)‑producing gut bacteria (e.g., Faecalibacterium prausnitzii) and lower basal hepatic AMP‑activated protein kinase (AMPK) activity will experience a greater reduction in postprandial glucose excursions and improved time‑in‑range after berberine supplementation, whereas those with low SCFA‑producer abundance or high hepatic AMPK activity will show minimal change.

Rationale

Berberine’s primary action is AMPK activation via mitochondrial inhibition [3], which enhances glucose uptake and suppresses hepatic gluconeogenesis. Parallel to this, berberine reshapes the gut microbiota, increasing the Bacteroidetes/Firmicutes ratio and SCFA‑producing taxa [2]. SCFAs, particularly butyrate, can activate intestinal AMPK and improve barrier function, indirectly influencing systemic glucose homeostasis. However, the magnitude of AMPK activation depends on the cellular energy state; tissues with already high AMPK phosphorylation have less capacity for further activation.

We propose a two‑hit model: (1) SCFA‑producing bacteria generate luminal butyrate that reaches the portal circulation and potentiates AMPK signaling in hepatocytes and enterocytes; (2) the efficacy of this potentiation is gated by the existing AMPK activity level. When baseline hepatic AMPK is low, the combined stimulus from berberine‑induced mitochondrial stress and SCFA signaling pushes AMPK above a activation threshold, markedly increasing GLUT2‑mediated glucose uptake and suppressing glucose output. When baseline AMPK is already high, additional stimulation yields diminishing returns, and the microbiome shift contributes little to net glucose flux.

Predictions

• Primary prediction: The interaction term (baseline F. prausnitzii abundance × baseline hepatic p‑AMPK level) will significantly predict the change in CGM‑derived glycemic variability (coefficient of variation, MAGE) and time‑in‑range (70‑180 mg/dL) after 4 weeks of 1500 mg/day berberine.
• Secondary prediction: Participants in the top quartile of SCFA‑producer abundance and bottom quartile of hepatic p‑AMPK will show ≥ 15 % reduction in glucose CV and ≥ 10 % increase in time‑in‑range, whereas the opposite quartile combination will show < 5 % change.

Experimental Design (Testable & Falsifiable)

1. Cohort: 60 adults with prediabetes or early type 2 diabetes (fasting glucose 5.6‑6.9 mmol/L).
2. Baseline assessments:
   • Stool shotgun metagenomics to quantify F. prausnitzii and other SCFA‑producer genes.
   • Peripheral blood mononuclear cell (PBMC) AMPK phosphorylation (p‑AMPK/total AMPK) as a proxy for hepatic activity (validated against liver biopsy in a subsample).
   • CGM installation for 2 weeks to establish baseline variability metrics.
3. Intervention: Berberine hydrochloride 1500 mg/day (divided BID) for 4 weeks.
4. Follow‑up: Repeat CGM for 2 weeks, collect stool and PBMC samples.
5. Analysis: Linear mixed‑effects model with change in glucose CV as outcome, fixed effects for baseline F. prausnitzii, baseline p‑AMPK, their interaction, age, BMI, and baseline HbA1c; random intercept for participant.

Falsifiability: If the interaction term is non‑significant (p > 0.05) and the simple main effects of baseline microbiome or AMPK alone do not predict CGM changes, the hypothesis is falsified. Conversely, a significant interaction supporting the directional prediction would confirm the mechanistic synergy.

Novel Mechanistic Insight

Beyond AMPK activation and microbiota modulation, we suggest that berberine may inhibit intestinal SGLT1‑mediated glucose absorption, an effect amplified by butyrate‑induced upregulation of GLUT2 in enterocytes. This dual action—reducing luminal glucose entry while enhancing hepatic glucose clearance—creates a microenvironment where SCFA‑producer abundance and baseline AMPK status jointly dictate the net glucose flux detectable only via high‑resolution CGM metrics.